ADHD children COVID-19 Pandemic, Behavioral and Pharmacological Treatment Outcomes , Attention Deficit Hyperactivity Disorder (ADHD) Children
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) was Thai people with 13-digit identification. 2) aged 14 years or younger during COVID-19 outbreak (after 3 April 2020). 3) were diagnosed Attention Deficit Hyperactivity Disorder (ADHD): ICD-10-TM codes F90 before and during COVID-19 outbreak. 4) had at least one patient data recorded or medical record before and during COVID-19 outbreak. 5) had records of pharmacological outcome or behavioral outcome. 6) had records of demographic data, Covid-19 pandemic data, or clinical and pharmacological factors.
Exclusion criteria
Exclusion criteria: 1) denied to participate in this project. 2) were diagnosed Autistic traits who would be represented the unobvious differentiation of pharmacological outcome and behavioral outcome. 3) loss of follow up or loss of contact information. 4) were study subjects with missing data on pharmacological outcome, behavioral outcome, demographic data, Covid-19 pandemic data, or clinical and pharmacological factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| behavioral outcomes survey date parents SNAP IV rating scale or health care provider assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacological outcomes survey date medication possession ratio (MPR) or medication adherence assessment by physician or medication withdraw period more than 6 months in the comparison of before and after COVID-19 pandemic | — |
Countries
Thailand
Contacts
Faculty of Pharmaceutical Sciences, Burapha University